Cue Biopharma Inc.

11.63+0.1300+1.13%Vol 754.44K1Y Perf -38.02%
Apr 13th, 2021 16:00 DELAYED
BID11.51 ASK12.26
Open11.80 Previous Close11.50
Pre-Market- After-Market-
 - -  - -%
Target Price
29.25 
Analyst Rating
Strong Buy 1.00
Potential %
151.51 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-67/-43/-16 
Value Ranking
★★★     52.22
Insiders Value % 3/6/12 mo.
-86/-63/-25 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-86/-59/-30 
Income Ranking
 —    -
Market Cap354.21M 
Earnings Rating
Sell
Price Range Ratio 52W %
4.20 
Earnings Date
6th May 2021

Today's Price Range

10.8611.80

52W Range

10.7531.69

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.51%
1 Month
-26.16%
3 Months
-8.64%
6 Months
-25.50%
1 Year
-38.02%
3 Years
-16.93%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CUE11.630.13001.13
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.33-0.37-12.12
Q03 2020-0.37-0.348.11
Q02 2020-0.41-0.387.32
Q01 2020-0.32-0.48-50.00
Q04 2019-0.42-0.3711.90
Q03 2019-0.44-0.3129.55
Q02 2019-0.56-0.4617.86
Q01 2019--0.54-
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.370.00-
6/2021 QR-0.39-5.41Negative
12/2021 FY-1.422.74Positive
12/2022 FY-1.5921.67Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.37
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume754.44K
Shares Outstanding30.46M
Trades Count3.03K
Dollar Volume5.27M
Avg. Volume311.63K
Avg. Weekly Volume283.13K
Avg. Monthly Volume288.63K
Avg. Quarterly Volume324.76K

Cue Biopharma Inc. (NASDAQ: CUE) stock closed at 11.63 per share at the end of the most recent trading day (a 1.13% change compared to the prior day closing price) with a volume of 754.46K shares and market capitalization of 354.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Cue Biopharma Inc. CEO is Daniel R. Passeri.

The one-year performance of Cue Biopharma Inc. stock is -38.02%, while year-to-date (YTD) performance is -7.03%. CUE stock has a five-year performance of %. Its 52-week range is between 10.75 and 31.69, which gives CUE stock a 52-week price range ratio of 4.20%

Cue Biopharma Inc. currently has a PE ratio of -7.90, a price-to-book (PB) ratio of 4.79, a price-to-sale (PS) ratio of 155.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -50.46%, a ROC of -66.50% and a ROE of -64.75%. The company’s profit margin is -%, its EBITDA margin is -1 011.70%, and its revenue ttm is $2.25 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Cue Biopharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. Cue Biopharma Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Cue Biopharma Inc. is Strong Buy (1), with a target price of $29.25, which is +151.51% compared to the current price. The earnings rating for Cue Biopharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cue Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cue Biopharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.64, ATR14 : 1.09, CCI20 : -97.00, Chaikin Money Flow : 0.01, MACD : -0.48, Money Flow Index : 18.33, ROC : -5.29, RSI : 48.79, STOCH (14,3) : 36.36, STOCH RSI : 0.72, UO : 50.10, Williams %R : -63.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cue Biopharma Inc. in the last 12-months were: Aaron Fletcher (Buy at a value of $455 919), Anish Suri (Option Excercise at a value of $48 620), Anish Suri (Sold 7 000 shares of value $140 122 ), Cameron Gray (Buy at a value of $151 500), Colin G. Sandercock (Option Excercise at a value of $150 000), Colin G. Sandercock (Sold 20 000 shares of value $400 010 ), Kenneth J. Pienta (Buy at a value of $40 980), Kenneth J. Pienta (Option Excercise at a value of $139 365), Kenneth J. Pienta (Sold 36 433 shares of value $550 641 ), Kerri-Ann Millar (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers.

CEO: Daniel R. Passeri

Telephone: +1 617 949-2680

Address: 21 Erie Street, Cambridge 02139, MA, US

Number of employees: 47

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

News

Stocktwits